NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.04 Insider Own1.20% Shs Outstand74.75M Perf Week17.53%
Market Cap3.12B Forward P/E- EPS next Y-6.00 Insider Trans-0.71% Shs Float68.53M Perf Month-17.71%
Income-368.60M PEG- EPS next Q-1.31 Inst Own84.70% Short Float9.11% Perf Quarter-51.03%
Sales37.90M P/S82.35 EPS this Y-57.60% Inst Trans1.65% Short Ratio5.12 Perf Half Y-65.86%
Book/sh12.76 P/B3.68 EPS next Y-5.80% ROA-32.70% Target Price136.65 Perf Year-27.20%
Cash/sh12.86 P/C3.65 EPS next 5Y30.00% ROE-41.00% 52W Range38.85 - 202.73 Perf YTD-60.30%
Dividend- P/FCF- EPS past 5Y-21.60% ROI- 52W High-76.85% Beta2.16
Dividend %- Quick Ratio6.90 Sales past 5Y14.90% Gross Margin- 52W Low20.82% ATR4.70
Employees485 Current Ratio6.90 Sales Q/Q76.60% Oper. Margin- RSI (14)43.41 Volatility9.64% 10.37%
OptionableYes Debt/Eq0.00 EPS Q/Q-185.70% Profit Margin- Rel Volume0.77 Prev Close48.33
ShortableYes LT Debt/Eq0.00 EarningsMay 05 BMO Payout- Avg Volume1.22M Price46.94
Recom1.90 SMA20-3.82% SMA50-21.41% SMA200-56.40% Volume942,310 Change-2.88%
Apr-28-22Initiated Credit Suisse Outperform $100
Feb-18-22Initiated William Blair Outperform $144
Feb-07-22Upgrade Oppenheimer Perform → Outperform $145 → $150
Jan-31-22Initiated Cowen Outperform
Jan-07-22Initiated Piper Sandler Overweight $171
Oct-05-21Initiated Guggenheim Buy $170
Sep-24-21Initiated Stifel Buy $173
Jun-28-21Reiterated H.C. Wainwright Buy $111 → $171
Jun-11-21Initiated H.C. Wainwright Buy $111
May-07-21Upgrade ROTH Capital Neutral → Buy $75 → $80
May-04-21Initiated RBC Capital Mkts Outperform $110
Mar-04-21Initiated JMP Securities Mkt Outperform $80
Dec-22-20Downgrade Robert W. Baird Outperform → Neutral $60
Oct-27-20Initiated Truist Buy $40
Oct-14-20Initiated Wells Fargo Overweight
Sep-18-20Initiated Goldman Buy $33
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
May-17-22 09:36AM  
May-11-22 01:40PM  
May-10-22 08:26AM  
May-06-22 03:02PM  
May-05-22 08:55AM  
07:30AM  
May-04-22 03:19PM  
May-03-22 08:25AM  
May-02-22 04:01PM  
07:30AM  
Apr-28-22 07:30AM  
Apr-21-22 01:04PM  
Apr-20-22 07:40AM  
Apr-11-22 10:12AM  
Mar-21-22 02:25PM  
Mar-17-22 09:36AM  
Mar-11-22 12:23PM  
Mar-10-22 10:11AM  
05:29AM  
Mar-09-22 04:01PM  
12:32PM  
Mar-03-22 06:29AM  
Mar-01-22 08:00PM  
05:44PM  
04:36PM  
02:04PM  
08:55AM  
07:30AM  
06:43AM  
Feb-28-22 08:15PM  
04:02PM  
04:01PM  
Feb-25-22 09:45AM  
Feb-24-22 09:15AM  
07:30AM  
Feb-23-22 02:45PM  
09:54AM  
08:00AM  
Feb-18-22 10:02AM  
Feb-17-22 03:02PM  
10:52AM  
07:30AM  
Feb-16-22 11:50AM  
Feb-15-22 04:10PM  
07:30AM  
Feb-10-22 11:55AM  
09:39AM  
Feb-08-22 08:08PM  
02:19PM  
07:03AM  
Feb-05-22 01:51PM  
Feb-04-22 10:11AM  
Feb-03-22 02:33PM  
07:30AM  
Feb-02-22 01:38PM  
Jan-29-22 04:25PM  
Jan-26-22 11:11AM  
Jan-19-22 09:38PM  
10:46AM  
Jan-13-22 03:56PM  
01:38PM  
06:03AM  
Jan-11-22 02:46PM  
Jan-06-22 01:43PM  
10:18AM  
07:30AM  
Jan-05-22 04:01PM  
07:30AM  
Jan-04-22 11:30AM  
Jan-03-22 06:00AM  
Dec-31-21 11:40AM  
Dec-30-21 11:59AM  
Dec-25-21 10:38PM  
Dec-23-21 08:09AM  
Dec-22-21 04:52PM  
Dec-20-21 07:30AM  
Dec-18-21 03:38AM  
Dec-17-21 09:04AM  
Dec-16-21 05:38PM  
09:38AM  
Dec-14-21 11:38PM  
05:17PM  
Dec-13-21 07:30AM  
Dec-10-21 02:02PM  
Dec-08-21 02:00PM  
Nov-22-21 07:30AM  
Nov-21-21 11:31AM  
Nov-12-21 09:34AM  
Nov-10-21 11:43AM  
10:48AM  
Nov-06-21 12:30PM  
Nov-05-21 07:30AM  
Nov-04-21 08:55AM  
07:30AM  
06:20AM  
Oct-28-21 03:26PM  
03:05PM  
07:30AM  
Oct-22-21 10:22AM  
Oct-21-21 07:30AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Goddard GlennEVP, Chief Financial OfficerJan 01Sale112.241,013113,6992,049Mar 03 07:38 PM
LEONARD JOHN MPresident and CEOJan 01Sale112.252,493279,852724,660Mar 04 09:07 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerJan 01Sale112.251,148128,8634,815Mar 03 08:03 PM
Lebwohl DavidEVP, Chief Medical OfficerJan 01Sale112.241,051117,96410,922Mar 03 08:00 PM
Lebwohl DavidEVP, Chief Medical OfficerNov 05Option Exercise12.622,40030,28811,114Nov 09 06:08 PM
Lebwohl DavidEVP, Chief Medical OfficerNov 05Sale132.722,400318,5358,714Nov 09 06:08 PM
Lebwohl DavidEVP, Chief Medical OfficerOct 14Option Exercise12.622,40030,28811,114Oct 15 07:02 PM
Lebwohl DavidEVP, Chief Medical OfficerOct 14Sale128.442,400308,2498,714Oct 15 07:02 PM
Crowley John FDirectorOct 11Option Exercise18.832,50047,0754,594Oct 13 04:15 PM
Crowley John FDirectorOct 11Sale119.552,500298,8752,094Oct 13 04:15 PM
Crowley John FDirectorOct 05Option Exercise18.8310,000188,30012,094Oct 07 05:41 PM
Crowley John FDirectorOct 05Sale130.5410,0001,305,3912,094Oct 07 05:41 PM
Lebwohl DavidEVP, Chief Medical OfficerSep 24Option Exercise12.627,92399,9888,714Sep 27 04:15 PM
Lebwohl DavidEVP, Chief Medical OfficerSep 21Option Exercise12.622,40030,2883,191Sep 23 05:48 PM
Lebwohl DavidEVP, Chief Medical OfficerSep 21Sale149.812,400359,544791Sep 23 05:48 PM
Goddard GlennEVP, Chief Financial OfficerSep 07Option Exercise14.583,48250,7683,482Sep 09 05:38 PM
Goddard GlennEVP, Chief Financial OfficerSep 07Sale180.123,482627,1780Sep 09 05:38 PM
LEONARD JOHN MPresident and CEOSep 01Option Exercise21.6244,735967,000764,040Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOSep 01Sale170.0044,7357,604,950719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 31Option Exercise18.9324,800469,37424,800Sep 01 07:30 PM
LEONARD JOHN MPresident and CEOAug 31Option Exercise14.5837,833551,605757,138Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOAug 31Sale155.0037,8335,864,115719,305Sep 01 08:21 PM
Goddard GlennEVP, Chief Financial OfficerAug 31Sale160.2224,8003,973,4560Sep 01 07:30 PM
Goddard GlennEVP, Chief Financial OfficerAug 30Option Exercise19.275,200100,2045,200Sep 01 07:30 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 30Option Exercise12.622,40030,2883,191Sep 01 07:32 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 30Option Exercise14.0197,0001,359,30099,391Sep 01 07:34 PM
LEONARD JOHN MPresident and CEOAug 30Option Exercise14.2338,804552,031758,109Sep 01 08:21 PM
LEONARD JOHN MPresident and CEOAug 30Sale155.9538,8046,051,353719,305Sep 01 08:21 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 30Sale158.042,400379,300791Sep 01 07:32 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 30Sale154.8397,00015,018,0542,391Sep 01 07:34 PM
Goddard GlennEVP, Chief Financial OfficerAug 30Sale155.785,200810,0820Sep 01 07:30 PM
LEONARD JOHN MPresident and CEOAug 23Option Exercise13.4027,139363,663746,444Aug 25 04:14 PM
LEONARD JOHN MPresident and CEOAug 23Sale152.0127,1394,125,416719,305Aug 25 04:14 PM
LEONARD JOHN MPresident and CEOAug 19Option Exercise13.4022,682303,939741,987Aug 20 06:14 PM
LEONARD JOHN MPresident and CEOAug 19Sale151.2822,6823,431,398719,305Aug 20 06:14 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 09Option Exercise12.622,40030,2883,191Aug 11 04:50 PM
Lebwohl DavidEVP, Chief Medical OfficerAug 09Sale164.052,400393,720791Aug 11 04:50 PM
Goddard GlennEVP, Chief Financial OfficerAug 05Option Exercise19.2720,000385,40020,000Aug 06 06:17 PM
Goddard GlennEVP, Chief Financial OfficerAug 05Sale151.0520,0003,021,0560Aug 06 06:17 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 04Option Exercise13.4026,000348,40028,391Aug 06 06:19 PM
Sepp-Lorenzino LauraEVP, Chief Scientific OfficerAug 04Sale138.2426,0003,594,3572,391Aug 06 06:19 PM
FORMELA JEAN FRANCOISDirectorJun 28Sale132.73553,37673,448,87910,000Jun 29 09:48 AM
FORMELA JEAN FRANCOISDirectorJun 14Sale87.37170,77914,921,294563,376Jun 15 09:51 AM
FORMELA JEAN FRANCOISDirectorJun 11Sale85.2330,9462,637,480734,155Jun 15 09:51 AM